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Abstract
Background: 5‐Fluorouracil (5‐FU) is administered with leucovorin (LV) to enhance clinical activity.
However, simultaneous administration is not feasible due to their chemical incompatibility, so conditions for
the maximum possible beneficial interaction cannot be met. To overcome this, we developed a novel
all‐in‐one, pH neutral stable solution of 5‐FU plus LV with β‐cyclodextrin (termed Deflexifol) and assessed its
safety and tolerability in a first‐in‐human phase I trial.
Methods: Patients with advanced solid malignancy received Deflexifol as weekly bolus (375–575 mg/m2) or
two‐weekly 46 h infusion (1200–3600 mg/m2) for six cycles in a 3+3 dose escalation design. Adverse events,
pharmacokinetics and tumor response rates were assessed by standard methods.
Results: Forty patients were treated (19 bolus, 21 infusional, median age 67) with no grade 4 adverse events
reported. Dose‐limiting toxicities of grade 3 diarrhea and myelosuppression were reported for the bolus
schedule at 575 mg/m2 (maximum tolerated dose 525 mg/m2), whereas none were reported for the
infusional schedule. The recommended phase II infusional dose was declared as 3,000 mg/m2, >25% that of
5‐FU used in standard‐of‐care regimens. Pharmacokinetic analyses showed evidence of inter‐patient
variability, with no evidence of saturation in clearance, and a trend to linear increase in AUC with dose.
Disease control rate was 64% despite most patients having failed previous 5‐FU regimens.
Conclusion: Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that
permitted by separate infusion of 5‐FU and LV. A phase II study evaluating Deflexifol is planned.
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5-Fluorouracil (5-FU) is administered with leucovorin (LV) to enhance clinical activity. However, 
simultaneous administration is not feasible due to their chemical incompatibility, so conditions for 
the maximum possible beneficial interaction cannot be met. To overcome this, we developed a 
novel all-in-one, pH neutral stable solution of 5-FU plus LV with β-cyclodextrin (termed 
Deflexifol) and assessed its safety and tolerability in a first-in-human phase I trial. 
METHODS 
Patients with advanced solid malignancy received Deflexifol as weekly bolus (375 mg/m² to 575 
mg/m²) or two-weekly 46 h infusion (1200 mg/m² to 3600 mg/m²) for 6 cycles in a 3+3 dose 
escalation design. Adverse events, pharmacokinetics, and tumor response rates were assessed by 
standard methods.  
RESULTS 
40 patients were treated (19 bolus, 21 infusional, median age 67) with no grade 4 adverse events 
reported. Dose-limiting toxicities of grade 3 diarrhea and myelosuppression were reported for the 
bolus schedule at 575 mg/m2 (maximum tolerated dose 525 mg/m²), whereas none were reported 
for the infusional schedule. The recommended Phase II infusional dose was declared as 3,000 
mg/m², > 25% that of 5-FU used in standard-of-care regimens. Pharmacokinetic analyses showed 
evidence of inter-patient variability, with no evidence of saturation in clearance, and a trend to 
linear increase in AUC with dose. Disease control rate was 64% despite most patients having failed 





Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that permitted 
by separate infusion of 5-FU and LV. A phase II study evaluating Deflexifol is planned. 
 





5-Fluorouracil (5-FU) in combination with its biomodulator leucovorin (LV; 5-formyl 
tetrahydrofolate, folinic acid or calcium folinate) remains a fundamental component of many 
efficacious chemotherapy regimens used in patients with colorectal, gastrointestinal, head and 
neck, and breast carcinoma.1 Most schedules of 5-FU/LV administration involve a bolus or short 
infusion (2 h) of LV followed by a bolus and/or an infusion of 5-FU. The requirement for separate 
administration of these drugs is due to the physical incompatibility of 5-FU (formulated as a highly 
alkaline solution to improve aqueous solubility) and the acidic LV, which otherwise results in 
precipitation of 5-FU and/or calcium carbonate.2-6 The incompatibility issues of 5-FU and LV 
dosing are not fully resolved by the use of sequential administration through central ports, as 
blockages are observed in these lines after repeated treatment cycles resulting in treatment 
interruption and discontinuation3,5 and/or reduced quality of life for patients.  
 
The rationale for co-administration of 5-FU and LV is based on sound pharmacological principles. 
Leucovorin acts to increase the intracellular pool of 5,10-methylene tetrahydrofolate (THF), 
leading to stabilization of the ternary complex (TS-fluorodeoxyuridine monophosphate-THF) 
thereby enhancing thymidylate synthase (TS) inhibition.7 Thus, concomitant delivery of 5-FU and 
LV should maximize anti-tumor activity. After LV administration, free folates reach peak serum 
levels within 10 min of injection and are cleared within ~ 6-8 h, with the half-life of the active l-
isomer of LV only 48 min;8 intratumoral THF levels fall rapidly after LV infusion.9 Given that 
most 5-FU infusional regimens run over 22–46 h, the lack of a pharmacokinetic overlap with LV 




Attempts at simultaneous rather than sequential administration of LV and 5-FU have suggested 
possible benefits, but confirmed the chemical incompatibilities between the two solutions. In a 
phase II study by Ardalan et al10, co-administration of 5-FU and LV into a dual lumen catheter 
increased the mean Overall Survival (OS) to 22 months in advanced colorectal cancer, a figure 
substantially higher than the 11.7 versus 10.5 months cited for LV/5-FU and 5-FU alone, 
respectively.11 However, 50% of patients experienced catheter blockages due to calcium carbonate 
formation and could not complete their treatment.2 In a more recent study of 29 patients with 
gastro-esophageal cancer who received 24 h infusions of 5-FU (variable dose) concomitantly with 
sodium folinate (to avoid calcium carbonate crystallization) catheter complications were still 
reported in 50% of patients, including thrombosis (17%) and line blockage (10%).12 
 
To address the potential for simultaneous administration of LV and 5-FU without adverse chemical 
interaction, we developed an all-in-one injectable reformulation of active ingredients 5-FU and 
LV at physiological pH, termed Deflexifol, using hydroxypropyl β-cyclodextrin as an FDA 
approved excipient.4 Incorporation of β-cyclodextrin improves the water solubility of 5-FU, 
negating the need for a strongly alkaline solution, thus preventing calcium carbonate precipitation 
and enabling a stable 5-FU/LV solution.4 The ratio of 5-FU:LV in Deflexifol is 15:1, which is 
similar to standard sequential low dose LV/5-FU regimens.1 In preclinical studies, Deflexifol 
showed equivalent tissue distribution and pharmacokinetics (PK) to LV followed by 5-FU, and 
was efficacious against colorectal and breast tumor models but with significantly reduced toxicity, 




Advances in chemotherapy use and design are important given that 5-FU remains a key treatment 
component for many cancer patients. Deflexifol was developed to maximize the clinical activity 
and safety profile of 5-FU and thus has the capacity to become a new standard fluoropyrimidine 
in chemotherapy regimens for a range of solid tumors. Herein we report the phase I results of 
Deflexifol in both bolus and infusional schedules. 
  
PATIENTS AND METHODS 
Patient eligibility 
Patients over the age of 18 with advanced or metastatic malignancies who had exhausted all 
standard treatments with an Eastern Cooperation Oncology Group performance status 0-2 were 
enrolled. A life expectancy of ≥12 weeks, and satisfactory renal, hepatic, and hematological 
function were required.  Exclusion criteria included patients with known deficiency of 
dihydropyrimidine dehydrogenase or a history of severe reactions to 5-FU or fluoropyrimidines, 
untreated brain metastases, patients who had completed chemotherapy or radiotherapy < 4 weeks 
prior, or who had severe comorbidities. Pregnant or breastfeeding women were also excluded. 
Study Design and Treatment 
This open-label single-center phase I study used a standard 3+3 dose escalation scheme to explore 
two treatment regimens. The primary objectives were to evaluate the safety and tolerability of 
Deflexifol in subjects with relapsed or refractory malignancy and to determine the maximum 
tolerated dose (MTD). Secondary objectives were 5-FU pharmacokinetic profile and anti-tumor 
activity. This study was approved by a local Human Investigations Committee (Bellberry Limited 
Approval #2014-05-259; TGA CTN 2014/0737)) and written informed consent was obtained from 




Patients were treated with Deflexifol (5-FU 15mg/ml/ LV 1mg/ml/ HP-β-CD 100mg/ml, pH 7.4 
+/- 0.1; formulated as ready-to-use solution) either as a bolus [based on the colorectal adjuvant 
Roswell Park (modified) fluorouracil and leucovorin weekly regimen; ID: 1271 v.4] or continuous 
infusion [based on the colorectal adjuvant de Gramont (modified) regimen; ID: 76 v.4].1 Treatment 
regimens were allocated based on clinical factors such as the presence of an existing central line. 
Bolus injections were administered within approximately 5 min via a peripheral cannula or central 
line weekly for 6 consecutive weeks every 8 weeks. Infusional injections were administered 
continuously over approximately 46 h via a central line, portacath or PICC line using a CADD 
Pump every 2 weeks for 12 weeks, followed by a 2 week break before patients were eligible for a 
repeat cycle of treatment. Patients continued Deflexifol while tolerated until disease progression. 
The dose escalation levels and number of patients enrolled in the bolus and infusion regimens are 
summarized in Supplementary Table 1.  
Safety Evaluations 
All adverse events (AEs) were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version V4.03. AE monitoring continued for 4 weeks 
after the final treatment, and monitoring of AEs related to Deflexifol was continued until 
stabilization or resolution. Dose limiting toxicities (DLTs) were assessed as AEs that were possibly 
related to study treatment, including any grade 3 or 4 non-hematologic toxicity with the exception 
of grade 3 nausea, vomiting, alopecia or diarrhea that resolved to a lower grade with supportive 
treatment within 7 days; febrile neutropenia, grade 4 neutropenia without fever lasting >7 days; 




In both schedules, MTD was declared as the dose level previous to the one at which two or more 
patients (out of 6) experienced DLTs.  
Pharmacokinetic Evaluations 
Blood samples were taken from patients on both the bolus and infusional regimens during the first 
and sixth dose of Deflexifol (bolus: pre, 10, 20, 60, 120 min and 24 h; infusion: pre and 2 h). Blood 
plasma levels of 5-FU and its metabolite 5-fluoro-5,6-dihydrouracil (5-FUH2) were measured by 
HPLC method14 with minor modifications. Area under the curve (AUC), clearance (CLR) and 
plasma half-lives (t1/2) were estimated for each patient to assess PK variability and adequacy of 
dosing in comparison to historical data.15,16 
Clinical Response and follow-up 
Responses were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 
criteria17, after approximately 6 – 8 weeks from baseline treatment. 
Statistical Analysis 
Descriptive statistics on patient characteristics, analysis of toxicities, and outcomes were 
performed for all patients. The Kaplan and Meier method was used to calculate progression-free 
and overall survival from the treatment start date to the date of death, or last review. PK values 
were calculated by program ‘PK Functions for Microsoft Excel’ using add-ins of PK1 and PK2 
functions to excel data analysis files, and Statistica (V12) was used for simple descriptive statistics 





40 patients (19 bolus, 21 infusion) were entered into the study. Patient characteristics are 
summarised in Table 1.  Patients were heavily pre-treated, with 13/40 (33%) of patients having 
previously undergone more than 5 lines of treatment and 34/40 (85%) had failed prior 
fluoropyrimidine treatment. The most common tumour types were colorectal (60%) and breast 
cancer (18%).  
Safety 
No grade 4 adverse events were observed in any patients (Table 2). Only eight patients (20 percent) 
reported treatment-related adverse events with a severity of grade 3. The DLT in the bolus schedule 
was grade 3 diarrhea and myelosuppression (pancytopenia) at 575 mg/m2 (dose of 5-FU). The 
bolus regimen MTD is thus 525 mg/m2, which exceeds that of current standard colorectal cancer 
adjuvant or metastatic weekly schedules (e.g., AIO, Roswell Park; 375 - 500 mg/m2)1 and with 
DLTs consistent with that reported in various weekly bolus 5-FU regimens.18,19 No DLT was 
observed in the infusion schedule up to dose level 5 (3600 mg/m2) (Table 2). However, it should 
be noted that no patients at this dose level completed a full treatment cycle due to disease 
progression, and it was decided to halt the trial at this point and consolidate the dose at 3000 
mg/m2.  
 
Overall, grade 1 - 2 fatigue and nausea were the most common toxicities observed among patients 
in both bolus and infusional regimens (Supplementary Table 2). No > grade 2 toxicity was noted 
at 375 - 475 mg/m2 bolus (dose levels 1- 3), or at 1200-1800 mg/m2 infusion (dose levels 1 - 2). 
No cardiac toxicity was observed. Grade 1 - 2 myelosuppression was only observed in the bolus 
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regimen. Three grade 3 adverse events were observed but these were related to disease progression 
and not to the study drug.  
Pharmacokinetics 
Of the 40 patients available for assessment of PK variability and adequacy of dosing, 38/40 patients 
treated at dose 1 and 24/32 patients treated at dose 6 had plasma levels assessed. All patients had 
measurable plasma concentrations of 5-FU and FUH2, with the FUH2 levels consistently greater 
than 5-FU (Supplementary Figures 1 and 2), as expected for patients with normal 
dihydropyrimidine dehydrogenase activity and 5-FU catabolism.14 PK showed evidence of inter-
patient variability consistent with known pharmacology of 5-FU. In the weekly bolus schedule 5-
FU CLR was 21-900 L/h, t1/2 0.11-0.52 h, with the intra-patient dose 6 CLR equal to 54-117% of 
dose 1 (Table 3) and there was a trend to increased AUC (mg.h/L) with dose (Supplementary 
Figure 1). The first 4 dose levels gave median AUCs that are well below the median AUC for 
toxicity in a study using a weekly bolus schedule of 500-864 mg/m2.15  With the infusion schedule, 
5-FU CLR (13 – 700 L/h) and AUC estimates were somewhat variable due to 3 patient outliers 
(>10-fold AUC values compared to the median; Supplementary Figure 1C, D) and some cases 
having insufficient data to thoroughly analyze, especially at dose 6 (Table 4). However, compared 
to historical PK data of 5-FU alone15,16, AUC was likely sub-therapeutic until > 525 mg/m2 in the 
bolus schedule, and for some patients with infusion at all dose cohorts. 
Response Rate 
A total of 36 of 40 patients were evaluable for response. Four patients withdrew from the study 
prior to imaging, due to toxicity, thus response could not be assessed. Of these 36 patients, there 
was 1 (3%) partial response, 22 (61%) stable disease, and 13 (36%) patients with progressive 
disease, with a disease control rate (partial response plus stable disease) of 23/36 (64%).  Figure 1 
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shows response rate (RECIST 1.1) in the 28 patients with measurable disease. Seven patients 
clinically progressed prior to cycle six and were withdrawn from the trial prior to imaging, and 
one patient did not have measurable disease as per RECIST 1.1.  Duration of clinical benefit for 
patients with a partial response or stable disease ranged from 1.6 – 13.1 months (median 3.8 
months). Of the 23 patients with disease control 11 (47%) were stable for at least 4 months. 
 
Based on all 40 patients, the median progression free survival was 2.6 months (95% CI, range 0.5 




Deflexifol is a rationally designed novel formulation of 5-FU with LV with potential to increase 
the clinical value of 5-FU. The co-administration of these two agents, rather than the currently 
employed sequential administration, has capacity for more sustained inhibition of TS as a 
consequence of longer duration of presence of both LV and 5-FU in tumor cells, with more 
profound and prolonged stability of the ternary complex.7. Indeed, the promising efficacy signals 
seen in this phase I study in heavily pretreated patients, including many with prior 5-FU exposure, 
implies that Deflexifol may display superior anti-tumor efficacy than sequential LV and 5-FU.  
 
Deflexifol also offers a more favorable toxicity profile than sequential LV and 5-FU, based on 
historical comparisons,20 and no catheter blockages or phlebitis were observed. The reduced 
toxicity of Deflexifol may be due in part to the pH neutral formulation in contrast to the alkaline 
pH of standard 5-FU. Preclinical rabbit models showed a marked reduction in phlebitis, a common 
and unreported problem, with Deflexifol compared to 5-FU.13 Similarly, the basic pH of standard 
5-FU was proposed to be a contributor to 5-FU cardiotoxicity through the presence of 
fluoroacetaldehyde impurities which are metabolized to the highly cardiotoxic compound 
fluoroacetate.21 We did not observe any cardiotoxicity in either the preclinical or this phase I study, 
although we acknowledge the limited sample size and absence of comprehensive cardiac 
investigations. On a practical level, Deflexifol also reduces nursing and drug administration time, 
since the need to administer LV separately is avoided which may have cost-saving implications.  
 
The current PK studies support the view that the pharmacology of 5-FU within Deflexifol is not 
substantially different to native 5-FU,15,22 with  mean half-life (10-12 min), mean clearance (130-
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170 L/h), and FUH2 levels being similar to our own data with 5-FU alone.23,24 We acknowledge 
PK variability in this trial due to both inter-patient variability, which is consistent with historical 
data for 5-FU16, and limited sampling frequency from the infusional schedule patients. However, 
the similar PK suggests that 5-FU is not bound by β-cyclodextrin to any extent, and that 5-FU 
metabolism is not impeded by the presence of β-cyclodextrin or LV.  In addition, the toxicity 
profile, generally consistent with the clinical experience of 5-FU alone, suggests that the additional 
components in Deflexifol, necessary to facilitate co-administration of 5-FU and LV, do not create 
any adverse interactions. 
 
The MTD for Deflexifol in the weekly bolus regimen was 525 mg/m2 which exceeds the current 
standard of care dose for bolus LV and 5-FU regimens (AIO, Roswell Park)1.  Given that DLT for 
the 46 h infusional regimen was not reached, even at the highest dose of 3600 mg/m2, for practical 
reasons the recommended phase II dose for further study is 3000 mg/m2 by 46 h infusion. This 
dose exceeds that used in current standard of care regimens with infusional 5-FU (e.g., modified 
de Gramont; 400 mg/m2 bolus + 2400 mg/m2 infusion).1  
 
The higher doses achieved with Deflexifol are more congruent with doses in schedules using 5-
FU alone,20 which suggests that the availability of LV in Deflexifol could possibly be 
compromised. Deflexifol was formulated to emulate low dose LV since several studies have shown 
no therapeutic advantage in using standard high (200 or 500 mg/m2) compared to standard low 
doses (20 mg/m2),25-27 and large inter-patient variability of tissue folate levels in colorectal cancer 
patients, regardless of LV dosing levels, has been reported28 (suggesting that assessment of plasma 
and tissue folates may not yield meaningful data). Further, low dose LV confers lower financial 
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cost and is reported to reduce hospitalization to manage chemotherapeutic toxicity.27 It is possible, 
however, to formulate Deflexifol with higher amounts of LV.4 
 
This phase I clinical trial has the following limitations. A limited number of dose levels were 
evaluated for pragmatic purposes; we did not expect that substantially higher doses of 5-FU could 
be tolerated when given as infusional Deflexifol compared to the sequential administration of LV 
and infusional 5-FU. Therefore, we could not identify a DLT or a MTD with precision for 
infusional Deflexifol. The PK limited sampling strategy was clearly not ideal to comfortably 
confirm each patients 5-FU metabolism parameters, and in future studies we recommend collection 
of plasma at more timepoints during (infusion) and after (bolus) administration. Despite these 
limitations, this study confirmed that LV and 5-FU can be mixed together and administered 
without unexpected side-effects, and with a 5-FU PK profile consistent with previous studies of 5-
FU alone. 
 
In conclusion, this phase I trial demonstrated that Deflexifol, a novel formulation of 5-FU together 
with LV managed by chemical manipulation using β-cyclodextrin, is safe and tolerable, and can 
be administered to cancer patients at 5-FU doses higher than those used in current clinical practice. 
In both a bolus and an infusion schedule, the toxicity spectrum of Deflexifol is minimal, with no 
unexpected adverse effects. Pharmacokinetic studies suggest that 5-FU in Deflexifol is distributed 
and metabolized similarly to native 5-FU, and indicate the potential for greater antitumor efficacy 
as a consequence of considerably longer duration of ternary complex formation. Furthermore, 
given that a positive 5-FU dose intensity versus tumor response relationship has been 
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demonstrated,20 the higher doses of 5-FU deliverable via Deflexifol also suggests that improved 





 1. Cancer Institute NSW: EviQ Cancer Treatments Online: Medical Oncology. 
https://www.eviq.org.au/  
 2. Ardalan B, Flores MR: A new complication of chemotherapy administered via 
permanent indwelling central venous catheter. Cancer 75:2165-8, 1995 
 3. Bruch HR, Esser M: Catheter occlusion by calcium carbonate during simultaneous 
infusion of 5-FU and calcium folinate. Onkologie 26:469-72, 2003 
 4. Locke JM, Stutchbury TK, Vine KL, et al: Development and assessment of novel 
all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant 
delivery of 5-fluorouracil and calcium folinate. Anticancer Drugs 20:822-31, 2009 
 5. Stiles ML, Allen LV, Jr., Tu YH: Stability of fluorouracil administered through 
four portable infusion pumps. Am J Hosp Pharm 46:2036-40, 1989 
 6. Trissel LA, Martinez JF, Xu QA: Incompatibility of fluorouracil with leucovorin 
calcium or levoleucovorin calcium. Am J Health Syst Pharm 52:710-5, 1995 
 7. Danenberg PV, Gustavsson B, Johnston P, et al: Folates as adjuvants to anticancer 
agents: Chemical rationale and mechanism of action. Crit Rev Oncol Hematol 106:118-31, 2016 
 8. Trave F, Rustum YM, Petrelli NJ, et al: Plasma and tumor tissue pharmacology of 
high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with 
advanced colorectal carcinoma. J Clin Oncol 6:1184-91, 1988 
 9. Houghton JA, Williams LG, de Graaf SSN, et al: Relationship between Dose Rate 
of [6RS]Leucovorin Administration, Plasma Concentrations of Reduced Folates, and Pools of 
5,10-Methylenetetrahydrofolates and Tetrahydrofolates in Human Colon Adenocarcinoma 
Xenografts. Cancer Res 50:3493-3502, 1990 
 10. Ardalan B, Chua L, Tian EM, et al: A phase II study of weekly 24-hour infusion 
with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-30, 1991 
 11. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin 
in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22:3766-75, 
2004 
 12. Karapetis CS, Cheong KA, Yip D, et al: A phase I and II trial of epirubicin, 
cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced 
esophagogastric carcinomas. Asia Pac J Clin Oncol 6:298-305, 2010 
 13. Stutchbury TK, Vine KL, Locke JM, et al: Preclinical evaluation of novel, all-in-
one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anticancer 
Drugs 22:24-34, 2011 
 14. Ackland SP, Garg MB, Dunstan RH: Simultaneous determination of 
dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. 
Anal Biochem 246:79-85, 1997 
 15. van Groeningen CJ, Pinedo HM, Heddes J, et al: Pharmacokinetics of 5-
fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation 
schedule. Cancer Res 48:6956-61, 1988 
 16. Saif MW, Choma A, Salamone SJ, et al: Pharmacokinetically guided dose 
adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer 
Inst 101:1543-52, 2009 
 17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in 
solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47, 2009 
18 
 
 18. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-
dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus 
plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 
15:808-15, 1997 
 19. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of 
fluorouracil: evidence of significant improvement of survival and quality of life in patients with 
advanced colorectal carcinoma. J Clin Oncol 7:1407-18, 1989 
 20. Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin for the 
treatment of colorectal cancer. Cancer 63:1036-44, 1989 
 21. Lemaire L, Malet-Martino MC, de Forni M, et al: Cardiotoxicity of commercial 5-
fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66:119-27, 1992 
 22. Hillcoat BL, McCulloch PB, Figueredo AT, et al: Clinical response and plasma 
levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 
38:719-24, 1978 
 23. Garg MB, Sevester JC, Sakoff JA, et al: Simple liquid chromatographic method for 
the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 
5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 774:223-30, 2002 
 24. Garg MB, Lincz LF, Adler K, et al: Predicting 5-fluorouracil toxicity in colorectal 
cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer 
107:1525-33, 2012 
 25. QUASAR: Comparison of flourouracil with additional levamisole, higher-dose 
folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR 
Collaborative Group. Lancet 355:1588-96, 2000 
 26. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of 
fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced 
colorectal cancer. J Clin Oncol 9:1967-72, 1991 
 27. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two 
schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin 
Oncol 12:14-20, 1994 
 28. Taflin H, Wettergren Y, Odin E, et al: Folate levels measured by LC-MS/MS in 
patients with colorectal cancer treated with different leucovorin dosages. Cancer Chemother 







Figure 1. Tumor response by patient and regimen, based on % change in sum of size of target 
lesions between baseline and after dose 6 (= Change from baseline) of treatment.  PD = progressive 
disease. PR = Partial remission. Patients in between the dotted lines exhibit stable disease. 28 
































Table 1. Patient characteristics 




Sex     
Male 7 (36) 12 (58) 
Female 12 (63) 9 (42) 
Age (y)     
Median (range) 64 (28 – 81) 67 (37 – 78) 
Primary Tumour Location     
Breast 5 (26) 2 (10) 
Colorectal 7 (37) 17 (80) 
Other Gastrointestinal 4 (21) 2 (10) 
Lung 3 (16) 0 (0) 
Prior 5-FU Treatment     
Yes 14 (74) 20 (95) 
No 5 (26) 1 (5) 
Lines of Previous Treatment     
<5 13 (68) 14 (67) 
>5 6 (32) 7 (33) 
 
Table 2. Treatment-related grade 3 or 4 adverse events by dose level and regimen 
 Bolus Dose Level  Infusion Dose Level 
1 2 3 4 5 1 2 3 4 5 
Grade  
No. of events 
Grade  
No. of events 
TOXICITY G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 
Diarrhea 0 0 0 0 0 0 1* 0 2 0 0 0 0 0 1# 0 0 0 0 0 
Nausea & vomiting 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1# 0 0 0 1 0 
Dyspnoea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Febrile neutropenia 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
Pancytopenia 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
Venous thrombosis 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
Raised ALT/AST 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*  Patient No. 40. This AE occurred after the 5th dose of their first cycle and was resolved by changing to a 4 weeks on 2 weeks off schedule. 
The patient then continued through another 2 full cycles with no AEs, declining further treatment in their 5th cycle 
#  Patient No. 17. These AEs occurred after the 3rd dose of their first cycle and were resolved by 25% dose reduction. The patient then continued 
on to another cycle with no AEs. 
 
Table 3. Pharmacokinetic parameters of 5-FU in bolus Deflexifol (mean ± SEM) 






CLR (L/h) t1/2 (h) N AUC 
(mg.h/L) 
CLR (L/h) t1/2 (h) 
1 (375) 3 6.5 ± 1.1 97.1 ± 11.2  3 7.7 ± 1.2 84.7 ± 16.7  
2 (425)  3 5.5 ± 2.0 188.0 ± 76.8  3 12.4 ± 2.5 68.0 ± 19.4  
3 (475)  3 7.1 ± 3.8 201.8 ± 101.4  3 7.5 ± 2.5 129.8 ± 42.2  
4 (525)  5 17.7 ± 8.2 148.4 ± 85.0  3 8.5 ± 3.8 378.3 ± 306.9  
5 (575)  4 18.4 ± 3.7 59.4 ± 9.9  2 26.5± 8.1 37.8 ± 9.6  
All 18 12.2 ± 2.7 135.6 ± 31.0 0.21± 0.02 14 11.5 ± 2.2 147.0 ± 66.1 0.22± 0.02 




Table 4. Pharmacokinetic parameters of 5-FU in infusional Deflexifol (mean ± SEM) 






CLR (L/h) N AUC (mg.h/L) CLR (L/h) 
1 (1200) 3 75.2 ± 67.1 191.4 ± 89.2 1 8.56 287.5 
2 (1800) 3 12.6 ± 1.04 229.3 ± 10.0 2 8.81 ± 0.1 260.1 ± 61.0 
3 (2400) 6 54.7 ± 37.0 209.1 ± 40.4 5 92.4 ± 73.2 183.4 ± 46.5 
4 (3000) 5 17.0 ± 2.2 355.3 ± 33.1 2 30.5 ± 17.6 322.2 ± 217.4 
5 (3600) 3 15.7 ± 5.6 496.2 ± 131.0 0 - - 
All 20 36.2 ± 14.5 289.1 ± 34.4 10 54.9 ± 36.9 236.9 ± 44.4 




Supplementary Table 1. Number of patients and doses received in each treatment schedule (bolus weekly × 6, and 46 h infusion every 2 weeks × 6) 

































and non-related AEs 
1 375 3 35 11.67 no toxicity 1200 3 19 6.33 1 × incomplete 
bowel obstruction at 
dose 3 cycle 1, 
withdrew consent 
2 425 3 34 11.33 no toxicity 1800 3 21 7 1 × ALT/AST 
increase due to 
unrelated infection, 
did not complete 




2400 6 62 10.33 Patient #25 received 
> 4 cycles, 12 
months treatment 
4 525 6 41 6.83 1 × grade 3 
diarrhea 
1 patient with 
suspected DPDD, 
did not complete 
3000 6 31.5 5.25 1 ×  SAE fall out of 
bed - attributed to 
rising Dysnopea, 
related to PD 
5 575 4 19 3.8 1 × grade 3 
diarrhea 
1 × grade 3 
diarrhea + 
myelosuppression 
3600 3 10 3.33 No patients 
completed a full 
treatment cycle due 
to PD 
 Total 19 159  Total 21 143.5  
Abbreviations: AE, adverse events; ALT/AST, aspartate transaminase/alanine transaminase; DPDD, dihydropyrimidine dehydrogenase deficiency; PD, 
Progressive disease; SAE, serious adverse event 
Supplementary Table 2. Treatment-related grade 1 and 2 adverse events by regimen 
 No. of events 
Bolus Infusion Total 
Abdominal pain 2 2 4 
Diarrhea 6 2 8 
Dyspnoea 4 5 9 
Fatigue 15               11 26 
Infection 2 4 6 
Myelosuppression 7 0 7 
Mucositis 4 5 9 
Nausea  8 6 14 
Raised ALT/AST 1 1 2 
Vomiting 2 0 2 
 
 







A . B o lu s  D o s e  1






















B . B o lu s  D o s e  6


























C . In fu s io n  D o s e  1


























D . In fu s io n  D o s e  6















S u p p le m e n ta ry  F ig u re  1
 
 
Supplementary Figure 1. Scatter dot plots showing relationship of area under the 5-FU 
plasma concentration × time curve (AUC) versus dose level (mg/m2) measured after 
administration of  (A. B.) bolus dose 1 and 6, or (C. D.) during infusion dose 1 and 6. • 
represent an individual patient with median values (−) for the cohort shown. For infusion 
dose 6, no samples were collected at the 3600 mg/m2 dose level.  Dashed lines indicate 
historical median AUC for toxicity using bolus1 or infusion2 regimens. 
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sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956-
61, 1988 
2 Saif MW, Choma A, Salamone S J, Chu E. Pharmacokinetically guided dose adjustment of 5-









A . B o lu s  D o s e  1





















B . B o lu s  D o s e  6





















C . In fu s io n  D o s e  1





















D . In fu s io n  D o s e  6




















Supplementary Figure 2. Scatter dot plots showing relationship of area under the FUH2 
plasma concentration-×-time curve (AUC) versus dose level (mg/m2) measured during 
administration of (A. B) bolus dose 1 and 6, or (C. D.) infusion dose 1 and 6. • represent an 
individual patient with median values (−) for the cohort shown. For infusion dose 6, no 
samples were collected at 1800 and 3600 mg/m2 dose levels. 
 
